Paper42428147
MRI biomarkers of primary CNS lymphoma outcome after MATRix: real world performance.
Menon N and 6 others. Front Oncol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. MRI biomarkers of primary CNS lymphoma outcome after MATRix: real world performance. Papers, record 42428147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42428147
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33481098 | From research to clinical practice: a European neuroradiological survey on quantitative advanced MRI implementation. | Eur Radiol | 2021 | https://conductscience.org/library/papers/33481098 | PubMed |
| 2 | 29054815 | Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. | Lancet Haematol | 2017 | https://conductscience.org/library/papers/29054815 | PubMed |
| 3 | 33615224 | Extent of radiological response does not reflect survival in primary central nervous system lymphoma. | Neurooncol Adv | 2021 | https://conductscience.org/library/papers/33615224 | PubMed |
| 4 | 19729544 | Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. | AJNR Am J Neuroradiol | 2010 | https://conductscience.org/library/papers/19729544 | PubMed |
| 5 | 30423172 | Introduction of novel agents in the treatment of primary CNS lymphoma. | Neuro Oncol | 2019 | https://conductscience.org/library/papers/30423172 | PubMed |
| 6 | 33996552 | Prognostic Role of Blood Markers in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate-Based Therapy. | Front Oncol | 2021 | https://conductscience.org/library/papers/33996552 | PubMed |
| 7 | 37713267 | Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas. | Neuro Oncol | 2024 | https://conductscience.org/library/papers/37713267 | PubMed |
| 8 | 32997181 | Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict chemotherapeutic responses and survival in primary central-nervous-system lymphoma. | Eur Radiol | 2021 | https://conductscience.org/library/papers/32997181 | PubMed |
| 9 | 36951966 | Prognostic value of metabolic tumor volume of extranodal involvement in diffuse large B cell lymphoma. | Ann Hematol | 2023 | https://conductscience.org/library/papers/36951966 | PubMed |
| 10 | 15955902 | Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/15955902 | PubMed |
| 11 | 37322012 | Primary central nervous system lymphoma. | Nat Rev Dis Primers | 2023 | https://conductscience.org/library/papers/37322012 | PubMed |
| 12 | 37511795 | Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy. | J Pers Med | 2023 | https://conductscience.org/library/papers/37511795 | PubMed |
| 13 | 36715098 | Pretreatment findings on magnetic resonance imaging in primary central nervous system lymphoma may predict overall survival duration. | Neuroradiol J | 2023 | https://conductscience.org/library/papers/36715098 | PubMed |
| 14 | 37056341 | A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis. | Front Oncol | 2023 | https://conductscience.org/library/papers/37056341 | PubMed |
| 15 | 32408414 | Apparent diffusion coefficient as a valuable quantitative parameter for predicting clinical outcomes in patients with newly diagnosed primary CNS lymphoma. | Blood Res | 2020 | https://conductscience.org/library/papers/32408414 | PubMed |
| 16 | 35223507 | PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS. | Front Oncol | 2022 | https://conductscience.org/library/papers/35223507 | PubMed |
| 17 | 32315266 | World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient. | Radiology | 2020 | https://conductscience.org/library/papers/32315266 | PubMed |
| 18 | 25802212 | Multi-centre reproducibility of diffusion MRI parameters for clinical sequences in the brain. | NMR Biomed | 2015 | https://conductscience.org/library/papers/25802212 | PubMed |
| 19 | 18494774 | Central nervous system lymphoma characterization by diffusion-weighted imaging and MR spectroscopy. | J Neuroimaging | 2008 | https://conductscience.org/library/papers/18494774 | PubMed |
| 20 | 27132696 | Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. | Lancet Haematol | 2016 | https://conductscience.org/library/papers/27132696 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42428147
GET https://conductscience.org/api/papers/v1/42428147/references?page=2